FAST NEWS: Junshi Bio’s Loss Balloons on High R&D Spending
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced on Monday it expects to report its revenue dropped 64.1% to 1.45 billion yuan ($2.14 billion) last year,…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK - As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
ZTE comeback stumbles on China telecoms spending slowdown
0763.HK 000063.SHE
- Cancer drug maker Genfleet joins Hong Kong IPO influx
